According to the report, the global hemostasis diagnostics market was valued at US$ 2.3 Bn in 2022 and is anticipated to expand at a CAGR of 8.5% from 2022 to 2030.
According to the report, the global hemostasis diagnostics market was valued at US$ 2.3 Bn in 2022 and is anticipated to expand at a CAGR of 8.5% from 2022 to 2030
The global hemostasis diagnostics market for the historical period 2017–2018 and forecast period 2022–2030, rise in prevalence of blood clotting disorders, high prevalence of cardiovascular diseases are projected to drive the global hemostasis diagnostics market during the forecast period
Download Sample @ https://qyresearchmedical.com/sample/111583
Rise in Prevalence of Blood Clotting Disorders and High Prevalence of Cardiovascular Diseases: Key Drivers
Bleeding easily when bruised is called abnormal bleeding. It can be due to blood clotting disorder, when the body is unable to produce clotting factors to stop bleeding. Hemophilia A and B, along with factor II, V, VII, X, or XII deficiencies are blood disorders identified with abnormal bleeding issues or blood coagulating issues. Over 440,000 people are suffering from hemophilia globally; of these 75% people are affected in less developed and developing countries
In 2018, it was estimated that over 13,600 people in the United States had been diagnosed with hemophilia A, while around 4,100 had been diagnosed with hemophilia B. Hemophilia is more common among males than females, with around 90% of hemophilia A cases worldwide occurring among males.
Prevalence of numerous diseases such as cancer, diabetes, and neurological disorders has increased due to rise in geriatric population and changing lifestyle in developing economies. Cardiovascular disease is one of the major factor in this. According to the WHO, cardiovascular diseases account for 17.5 million deaths across the world, which is about 31% of all the deaths globally. Deep vein thrombosis is one of the cardiovascular complications, wherein blood clots are formed within the deep vein, commonly in the legs. According to the CDC, about 900,000 people could be affected each year in the U.S. It is suggested that around 60,000 to 100,000 people in the U.S. die due to this disease.
Advancement in Technology Leading to Easy Usage Boost Market Growth
Hemostasis diagnostics devices have come a long way from quantifying optical density of clot in a cuvette to detection of clotting factors. Advancements in hemostasis technology has led to development of wide range of products that have enabled clinicians to provide proper emergency assistance to patients.
The concept of automation has extended to hemostasis diagnostics as well, which is less labor intensive, rapid, and easy-to-use. Current technologies include automation of blood coagulation analyzers, flow cytometers, microarrays, and PCR. Combination of these technologies has increased the yield and productivity.
High Cost of Automated Instruments to Hamper Market
Advancements in technology in hemostasis diagnostics instruments carry a heavy price tag. Laboratories cannot afford high cost instruments. Therefore, there is a need for basic coagulation instruments, which are cost effective and easy-to-use.
At a list price of US$ 49,000, the Accuri C6 is in the lower-middle range of benchtop flow cytometer instruments, which start at $14,000 for the closed-architecture Muse Cell Analyzer from EMD Millipore. Most instruments cost $75,000 to $100,000 for a two-laser, four- to six-color instrument.
High instrument cost can increase testing expenditure, which can restrain the global hemostasis diagnostics market during the forecast period
Global Hemostasis Diagnostics Market: Competitive Landscape
This report profiles major players in the global hemostasis diagnostics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The global hemostasis diagnostics market is highly fragmented, with the presence of a number of international as well as regional players
Leading players operating in the global hemostasis diagnostics market are
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- Nihon Kohden Corporation
- Sysmex Corporation
- Siemens Healthineers
- Instrumentation Laboratory
- Danaher Corporation (Beckman Coulter)
- Grifols
- S.A. among others
Global Hemostasis diagnostics market: Key Developments
Key players in the global hemostasis diagnostics market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global hemostasis diagnostics market. A few expansion strategies adopted by players operating in the global hemostasis diagnostics market are:
In July 2020, Sysmex Corporation launched of new products in the hemostasis field: the Automated Blood Coagulation Analyzers CN-6500/CN-3500. These new offerings from Sysmex come with a measuring unit using the chemiluminescence enzyme immunoassay methodology (CLEIA), which we cultivated in our Automated Immunoassay Systems HISCL-5000/HISCL-800 (HISCL), on top of the unique features of the Automated Blood Coagulation Analyzers CN-6000/CN-3000, making it possible to measure blood coagulation testing parameters, including molecular markers for blood coagulation with a single device.
In May 2018, HORIBA UK Ltd launched new Yumizen G range of instruments and reagents for Haemostasis solutions.
In April 2017, Starch Medical Inc. expanded its hemostasis portfolio with launch of SuperClot Hemostat in Europe.
The report on the global hemostasis diagnostics market discussed individual strategies, followed by company profiles of manufacturers of hemostasis diagnostics devices. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global hemostasis diagnostics market.
Hemostasis Diagnostics Market to Observe Growth in High Prevalence of Coagulation Disorders
Coagulation disorders are issues with the body’s capacity to clot blood. These conditions may result in hemorrhage or thrombosis. Coagulatory disorders can be caused by a variety of factors. These conditions may be developed or inherited. Platelet dysfunction, von Willebrand disease, and hemophilia are some of the most common coagulation disorders that can trigger bleeding. In addition to that, disseminated intravascular coagulation, deficiency of Vitamin K, and other clotting factor defects are other causes of coagulation disorders that may lead to bleeding. These factors are likely to work in favor of the global hemostasis diagnostics market in near future. Hemophilia A is four times more common than hemophilia B, as per the National Hemophilia Foundation. In the United States, there are about 20,000 people suffering from hemophilia.
Rapid Technological Progress to Create Ample Opportunities for the Market
Technology progresses at a breakneck rate and it is likely to play an important role in the expansion of the global hemostasis diagnostics market in the years to come. Blood coagulation control has become increasingly important in recent years for assessing bleeding risk in comprehensive surgical procedures and dialysis, diagnosing hemorrhage causes, and designing anticoagulant medications. It is also utilized for determining the effectiveness of hemostatic therapies. From calculating the optical density of a clot in a cuvette to identifying factors of clotting, hemostasis diagnostics have come a long way. Platelet function analyzers, functional assays of particular coagulation proteins, molecular typing immunologic assays, chromogenic assays, and flow cytometry, and are examples of these techniques. These technical developments have resulted in improved sensitivity, accuracy, productivity, and capability, and eventually it leads to better patient clinical care.
There are two types of bleeding disorders: acquired and hereditary. Inherited bleeding disorders are caused by a lack of coagulation factors and are caused by a genetic predisposition. Circumstances that can occur at any point of time during a person’s lifespan can induce acquired bleeding disorders. Hereditary bleeding disorders are caused by a lack or deficiency of particular clotting proteins, which function as procoagulants in the clotting cascade by precise interactions. Such factors are estimated to benefit global hemostasis diagnostics market in near future.
Key Questions Answered in Global Hemostasis Diagnostics Market Report
- What is the scope of growth of product companies in the global hemostasis diagnostics market?
- What will be the Y-o-Y growth of the global hemostasis diagnostics market between 2022 and 2030?
- What is the influence of changing trends in technologies on the global hemostasis diagnostics market?
- Will North America continue to be the most profitable market for hemostasis diagnostics devices providers?
- Which factors are anticipated to hamper the growth of the global hemostasis diagnostics market during the forecast period?
- Which are the leading companies in the global hemostasis diagnostics market?
Global Hemostasis Diagnostics Market – Segmentation
Product Type
- Laboratory Systems
- Consumables
- Point-of-Care Testing Systems
Product Type
- Prothrombin Test Time (PT)
- Activated partial thromboplastin time (APTT)
- Fibrinogen degradation products (FDP)
- Activated Clotting Time
- Platelet Aggregation Test
- D Dimer
- Others
End-user
- Hospital/Clinics
- Independent Diagnostic Laboratories
- Home Care Settings
- Others
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/111583/2900
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
About Us
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/
https://twitter.com/qyresearchmedi